AT502651T - Internalization of DNA by use of conjugates of poly-L-lysine and a peptidligands the integrin receptor - Google Patents

Internalization of DNA by use of conjugates of poly-L-lysine and a peptidligands the integrin receptor

Info

Publication number
AT502651T
AT502651T AT95937946T AT95937946T AT502651T AT 502651 T AT502651 T AT 502651T AT 95937946 T AT95937946 T AT 95937946T AT 95937946 T AT95937946 T AT 95937946T AT 502651 T AT502651 T AT 502651T
Authority
AT
Austria
Prior art keywords
peptidligands
internalization
conjugates
lysine
dna
Prior art date
Application number
AT95937946T
Other languages
German (de)
Inventor
Stephen Lewis Hart
Richard Paul Harbottle
Original Assignee
Ich Productions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9423231A priority Critical patent/GB9423231D0/en
Priority to GB9423308A priority patent/GB9423308D0/en
Priority to GBGB9512822.9A priority patent/GB9512822D0/en
Application filed by Ich Productions Ltd filed Critical Ich Productions Ltd
Priority to PCT/GB1995/002706 priority patent/WO1996015811A1/en
Publication of AT502651T publication Critical patent/AT502651T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT95937946T 1994-11-17 1995-11-17 Internalization of DNA by use of conjugates of poly-L-lysine and a peptidligands the integrin receptor AT502651T (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB9423231A GB9423231D0 (en) 1994-11-17 1994-11-17 DNA compositions
GB9423308A GB9423308D0 (en) 1994-11-18 1994-11-18 DNA compositions
GBGB9512822.9A GB9512822D0 (en) 1995-06-23 1995-06-23 DNA Compositions
PCT/GB1995/002706 WO1996015811A1 (en) 1994-11-17 1995-11-17 Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand

Publications (1)

Publication Number Publication Date
AT502651T true AT502651T (en) 2011-04-15

Family

ID=27267477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937946T AT502651T (en) 1994-11-17 1995-11-17 Internalization of DNA by use of conjugates of poly-L-lysine and a peptidligands the integrin receptor

Country Status (8)

Country Link
US (1) US6083741A (en)
EP (1) EP0792166B1 (en)
JP (1) JPH10509166A (en)
AT (1) AT502651T (en)
AU (1) AU3876695A (en)
CA (1) CA2204254C (en)
DE (1) DE69536153D1 (en)
WO (1) WO1996015811A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
WO1997023608A1 (en) * 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
EP2298728A1 (en) 1998-11-12 2011-03-23 Life Technologies Corporation Transfection reagents
SE9900134D0 (en) * 1999-01-15 1999-01-15 A & Science Invest Ab A Method for Introducing Substances into cells, and use of said method
KR100784120B1 (en) * 2000-06-02 2007-12-12 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 EthylenedicysteineEC-drug conjugates
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2002024232A2 (en) * 2000-09-25 2002-03-28 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
EP1610751A4 (en) * 2001-04-26 2006-05-24 Univ Texas Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
WO2003078576A2 (en) * 2002-03-12 2003-09-25 Nitto Denko Corporation Vector for transfection of eukaryotic cells
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
CA2505537A1 (en) * 2002-11-07 2004-05-27 Board Of Regents, The University Of Texas System Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
EP1587524A4 (en) * 2003-01-09 2006-07-26 Arizeke Pharmaceuticals Inc Compositions and methods for targeted biological delivery of molecular carriers
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US20060068469A1 (en) * 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
NL1027479C2 (en) * 2004-10-21 2006-05-01 Synvolux Ip B V Protection of biologically active molecules with the aid of amphifielen.
AT456960T (en) * 2006-03-31 2010-02-15 Council Scient Ind Res New integrin-binding rgd lipopeptides with gene transfer activities
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
GB0610636D0 (en) * 2006-05-30 2006-07-05 Univ London Materials and complexes for the delivery of biologically-active material to cells
US20100159450A1 (en) 2006-06-23 2010-06-24 Susanne Wagner Dpyd gene variants and use thereof
US20080107598A1 (en) * 2006-10-05 2008-05-08 Yang David J Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications
EP2129388B1 (en) * 2007-02-23 2012-09-12 The Research Foundation Of State University Of New York Rna targeting compounds and methods for making and using same
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
EP2257280A4 (en) * 2008-02-26 2015-09-09 Aparna Biosciences Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
CN103269713B (en) 2010-10-11 2016-01-20 诺华有限公司 Antigen delivery platform
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
ES2656050T3 (en) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Immunogenic compositions combination and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CN104105504A (en) 2011-10-11 2014-10-15 诺华股份有限公司 Recombinant polycistronic RNA molecules
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
JP2015522580A (en) 2012-07-06 2015-08-06 ノバルティス アーゲー Immunological compositions and the use thereof
CN104902925A (en) 2013-01-10 2015-09-09 诺华股份有限公司 Influenza virus immunogenic compositions and uses thereof
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
GB201604235D0 (en) 2016-03-11 2016-04-27 Ucl Business Plc Lipids and complexes for the delivery of biologically-active material to cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS586971B2 (en) * 1979-12-26 1983-02-07 Hitachi Ltd
JPH0524537B2 (en) * 1988-04-04 1993-04-08 Tokyo Shibaura Electric Co
JPH04221397A (en) * 1990-12-20 1992-08-11 Fuji Photo Film Co Ltd Water-soluble polypeptide derivative and its use
AT329624T (en) * 1992-05-21 2006-07-15 Diatide Inc Technetium-99m labeled peptides for imaging thrombus
AU6254494A (en) * 1993-02-16 1994-09-14 Virginia Tech Intellectual Properties, Inc. Polyelectrolyte dna conjugation and genetic transformation of an animal
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides

Also Published As

Publication number Publication date
WO1996015811A1 (en) 1996-05-30
CA2204254C (en) 2010-02-16
CA2204254A1 (en) 1996-05-30
AU3876695A (en) 1996-06-17
US6083741A (en) 2000-07-04
JPH10509166A (en) 1998-09-08
EP0792166A1 (en) 1997-09-03
EP0792166B1 (en) 2011-03-23
DE69536153D1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
DK2301580T3 (en) The container with the anti-VEGF antibodies
DK0753531T3 (en) The radiation-curable aqueous dispersions, their preparation and use
NO20005809D0 (en) A hepatocyttmålrettet polyetylenglykolpodet polymer poly-L- lysine genbærer
ID20039A (en) microemulsion
DE69829830D1 (en) Weglenkungsverfahren using a genetic algorithm
NO2006016I1 (en) 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
NO993790L (en) Synthetic jet fuels and process
DE60005864D1 (en) Multicomponent fibers and fabric prepared therefrom area
TR199600261A2 (en) Price new catalysts produce polyolefins.
DE60010234D1 (en) 2-amino-6-anilino-purine, and their use as medicaments
NO964281L (en) Papermaking pigment, preparation and use thereof
DE60036472D1 (en) Press Flow measurement using unstable
AT455882T (en) Multicomponent fibers and fabric prepared therefrom area
NL300429I1 (en) quinazoline
FR2734496B1 (en) emulsifying composition based on alkylpolyglycosides and its uses
BR9710979B1 (en) composiÇço prepared from the product of modified carbano.
DK0610334T3 (en) Nonpeptidyl integrin with specificity for the GPIIb IIIA receptor
FI954729A (en) Improved absorbenttiosia, the dispersants for the improved liquid density and basis weight through small receiving zone
NL1011493A1 (en) 1-alkoxy-polyalkyl-derivatives and their use as control agents for the polymerization.
DE69620871T2 (en) The supported catalyst activator
NL1002248C2 (en) New connections.
NL300335I1 (en) Human monoclonal antibodies against epidermal growth factor receptor
NO322509B1 (en) Liquid gonadotropin-containing formulation, process feed for the preparation, and the use thereof.
NO20001768L (en) Viruskapsomervaksine, fremgangsmÕte the preparation and use thereof
AT267884T (en) On titanium alloy based dispersion strengthened composite material

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties